Early ovarian cancer: a review of its genetic and biologic factors, detection, and treatment.

[1]  H. Averette,et al.  Localized ovarian cancer in the elderly: The gynecologic oncology group experience , 2010, Cancer.

[2]  K. Buetow,et al.  Characterization of chromosome 9 in human ovarian neoplasia identifies frequent genetic imbalance on 9q and rare alterations involving 9p, including CDKN2. , 1995, Cancer research.

[3]  A. Jeffreys,et al.  A somatic BRCA1 mutation in an ovarian tumour , 1995, Nature Genetics.

[4]  L. Twiggs,et al.  Blood flow characteristics of ovarian tumors: implications for ovarian cancer screening. , 1995, American journal of obstetrics and gynecology.

[5]  M. Skolnick,et al.  A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. Implications for presymptomatic testing and screening. , 1995, JAMA.

[6]  Patrick Dowd,et al.  Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families , 1994, Nature Genetics.

[7]  Francis S. Collins,et al.  Mutations in the BRCA1 gene in families with early-onset breast and ovarian cancer , 1994, Nature Genetics.

[8]  J. Rommens,et al.  Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families , 1994, Nature Genetics.

[9]  L. Cannon-Albright,et al.  A P1-based physical map of the region from D17S776 to D17S78 containing the breast cancer susceptibility gene BRCA1. , 1994, Human molecular genetics.

[10]  M. Skolnick,et al.  BRCA1 mutations in primary breast and ovarian carcinomas. , 1994, Science.

[11]  K. Buetow,et al.  A common region of deletion on chromosome 17q in both sporadic and familial epithelial ovarian tumors distal to BRCA1. , 1994, American journal of human genetics.

[12]  S. Seal,et al.  Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. , 1994, Science.

[13]  K H Buetow,et al.  A comprehensive human linkage map with centimorgan density. Cooperative Human Linkage Center (CHLC). , 1994, Science.

[14]  S. Self,et al.  Ovarian tumors in a cohort of infertile women. , 1994, The New England journal of medicine.

[15]  A. Godwin,et al.  Screening, Imaging, and Early Diagnosis of Ovarian Cancer , 1994, Clinical obstetrics and gynecology.

[16]  M. King,et al.  Familial male breast cancer is not linked to the BRCA1 locus on chromosome 17q , 1994, Nature Genetics.

[17]  T. Flotte,et al.  Prognostic significance of DNA content in epithelial ovarian cancer. , 1994, Gynecologic oncology.

[18]  R. Ozols.  Treatment of ovarian cancer: current status. , 1994, Seminars in oncology.

[19]  S. Cha,et al.  Activation of c‐erbB‐2 and prognosis in ovarian carcinoma. Comparison with histologic type, grade, and stage , 1994, Cancer.

[20]  B. Bromley,et al.  Comparison Between Sonographic Morphology and Doppler Waveform for the Diagnosis of Ovarian Malignancy , 1994, Obstetrics and gynecology.

[21]  L. Valentin,et al.  Limited Contribution of Doppler Velocimetry to the Differential Diagnosis of Extrauterine Pelvic Tumors , 1994, Obstetrics and gynecology.

[22]  J. Schlesselman,et al.  The Estimated Effect of Oral Contraceptive Use on the Cumulative Risk of Epithelial Ovarian Cancer , 1994, Obstetrics and gynecology.

[23]  P. Franzone,et al.  High‐Risk Early‐Stage Ovarian Cancer Randomized Clinical Trial Comparing Cisplatin Plus Cyclophosphamide versus Whole Abdominal Radiotherapy , 1994, American journal of clinical oncology.

[24]  P. Humphrey,et al.  Overexpression of p53 is not a feature of benign and early-stage borderline epithelial ovarian tumors. , 1994, Gynecologic oncology.

[25]  W. Willett,et al.  Tubal Ligation, Hysterectomy, and Risk of Ovarian Cancer: A Prospective Study , 1993 .

[26]  A. Knudson,et al.  Antioncogenes and human cancer. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[27]  J. Trent,et al.  WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.

[28]  R. Bast,et al.  Elevation of multiple serum markers in patients with stage I ovarian cancer. , 1993, Journal of the National Cancer Institute.

[29]  W. Collins,et al.  Whole chromosome 17 loss in ovarian cancer , 1993, Genes, chromosomes & cancer.

[30]  W. Foulkes.  Tumour suppressor genes in ovarian cancer. , 1993, BMJ.

[31]  A. Knudson.  All in the (cancer) family , 1993, Nature genetics.

[32]  J. Roth,et al.  A retroviral wild-type p53 expression vector penetrates human lung cancer spheroids and inhibits growth by inducing apoptosis. , 1993, Cancer research.

[33]  R. Bast,et al.  Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. , 1993, Journal of the National Cancer Institute.

[34]  J. Prat,et al.  Morphologic Precursors of Ovarian Epithelial Tumors , 1993, Obstetrics and gynecology.

[35]  A. Berchuck,et al.  OVX1 radioimmunoassay complements CA-125 for predicting the presence of residual ovarian carcinoma at second-look surgical surveillance procedures. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  R. Barakat,et al.  Platinum‐based chemotherapy of high‐risk stage I epithelial ovarian cancer following comprehensive surgical staging , 1993, Obstetrics and gynecology.

[37]  M. Birrer,et al.  p53 and Ki-ras gene mutations in epithelial ovarian neoplasms. , 1993, Cancer research.

[38]  V. Abeler,et al.  Analysis of prognostic factors in stage I epithelial ovarian carcinoma: importance of degree of differentiation and deoxyribonucleic acid ploidy in predicting relapse. , 1993, American journal of obstetrics and gynecology.

[39]  J. Nesland,et al.  The expression of c-erbB-2 (HER-2/neu) oncogene in invasive ovarian malignancies , 1993, International Journal of Gynecologic Cancer.

[40]  M. Carcangiu,et al.  Allelic loss in ovarian cancer , 1993, International journal of cancer.

[41]  A. Thor,et al.  p53 gene mutations and protein accumulation in human ovarian cancer. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[42]  W. Foulkes,et al.  Very frequent loss of heterozygosity throughout chromosome 17 in sporadic ovarian carcinoma , 1993, International journal of cancer.

[43]  Bratin Saha,et al.  Allelic loss on chromosome 17 in human ovarian cancer , 1993, International journal of cancer.

[44]  J. Grudzinskas,et al.  Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography. , 1993, BMJ.

[45]  R. Berkowitz,et al.  Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy. , 1993, Cancer research.

[46]  I. Vergote,et al.  Intraperitoneal radioactive phosphorus therapy in ovarian carcinoma. Analysis of 313 patients treated primarily or at second‐look laparotomy , 1993, Cancer.

[47]  D. Easton,et al.  Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. , 1993, American journal of human genetics.

[48]  H. Fox.  Pathology of early malignant change in the ovary. , 1993, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[49]  R. Bast,et al.  A deletion unit on chromosome 17q in epithelial ovarian tumors distal to the familial breast/ovarian cancer locus. , 1993, Cancer research.

[50]  W. Hoskins.  Surgical staging and cytoreductive surgery of epithelial ovarian cancer , 1993, Cancer.

[51]  J. Chmiel,et al.  National survey of ovarian carcinoma. I. A patient care evaluation study of the American College of Surgeons. , 1993, Cancer.

[52]  P. Humphrey,et al.  Clonal origin of epithelial ovarian carcinoma: analysis by loss of heterozygosity, p53 mutation, and X-chromosome inactivation. , 1992, Journal of the National Cancer Institute.

[53]  A. Whittemore,et al.  Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. , 1992, American journal of epidemiology.

[54]  J Halpern,et al.  Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. I. Methods. Collaborative Ovarian Cancer Group. , 1992, American journal of epidemiology.

[55]  Y. Nakamura,et al.  Fine-scale deletion mapping of the distal long arm of chromosome 6 in 70 human ovarian cancers. , 1992, Cancer research.

[56]  J. Cheng,et al.  AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[57]  D. Eccles,et al.  Early loss of heterozygosity on 17q in ovarian cancer. The Abe Ovarian Cancer Genetics Group. , 1992, Oncogene.

[58]  K. Kerlikowske,et al.  Should women with familial ovarian cancer undergo prophylactic oophorectomy? , 1992, Obstetrics and gynecology.

[59]  D. Easton,et al.  Allele losses in the region 17q12–21 in familial breast and ovarian cancer involve the wild–type chromosome , 1992, Nature Genetics.

[60]  M. Piver,et al.  Five-year survival for stage IC or stage I grade 3 epithelial ovarian cancer treated with cisplatin-based chemotherapy. , 1992, Gynecologic oncology.

[61]  I. Jacobs,et al.  Strategies for improving the specificity of screening for ovarian cancer with tumor‐associated antigens CA 125, CA 15‐3, and TAG 72.3 , 1992, Obstetrics and gynecology.

[62]  J. Marks,et al.  p53 overexpression in formalin-fixed, paraffin-embedded tissue detected by immunohistochemistry. , 1992, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[63]  M. Friedlander,et al.  Amplification of HER-2/neu oncogene in human ovarian cancer , 1992, International Journal of Gynecologic Cancer.

[64]  P. Humphrey,et al.  Overexpression and mutation of p53 in endometrial carcinoma. , 1992, Cancer research.

[65]  I. Thaler,et al.  Differentiating Malignant From Benign Ovarian Tumors With Transvaginal Color Flow Imaging , 1992, Obstetrics and gynecology.

[66]  F. Kikkawa,et al.  Antenatal Classification of Hydrops Fetalis , 1992 .

[67]  P. Dottino,et al.  A phase II trial of adjuvant cisplatin and doxorubicin in stage I epithelial ovarian cancer. , 1991, Gynecologic oncology.

[68]  R. Bast,et al.  Increased serum levels of macrophage colony-stimulating factor in ovarian cancer. , 1991, American journal of obstetrics and gynecology.

[69]  T. Bourne,et al.  Ultrasound screening for familial ovarian cancer , 1991, Gynecologic oncology.

[70]  N. Ragni,et al.  Adjuvant cisplatin-based chemotherapy for stage I and II ovarian cancer: a 7-year experience. , 1991, European journal of cancer.

[71]  Y. Nakamura,et al.  Allelotype of human ovarian cancer. , 1991, Cancer research.

[72]  C. la Vecchia,et al.  The epidemiology of ovarian cancer. , 1991, Gynecologic oncology.

[73]  A. Okamoto,et al.  Frequent allelic losses and mutations of the p53 gene in human ovarian cancer. , 1991, Cancer research.

[74]  T. Maudelonde,et al.  p53 mutations in ovarian cancer: a late event? , 1991, Oncogene.

[75]  J. van Nagell,et al.  Ovarian cancer screening , 1991, Cancer.

[76]  M. Yu,et al.  Distinction of low grade from high grade human ovarian carcinomas on the basis of losses of heterozygosity on chromosomes 3, 6, and 11 and HER-2/neu gene amplification. , 1991, Cancer research.

[77]  G. Lenoir,et al.  Familial breast-ovarian cancer locus on chromosome 17q12-q23 , 1991, The Lancet.

[78]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[79]  K. Kinzler,et al.  Identification of p53 as a sequence-specific DNA-binding protein , 1991, Science.

[80]  J. Marks,et al.  Genetic basis for p53 overexpression in human breast cancer. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[81]  W. Lee,et al.  Allele loss at the retinoblastoma locus in human ovarian cancer. , 1991, Journal of the National Cancer Institute.

[82]  R. A. Metcalf,et al.  Mutational hot spot in the p53 gene in human hepatocellular carcinomas , 1991, Nature.

[83]  G. Fleuren,et al.  Watch and wait after careful surgical treatment and staging in well‐differentiated early ovarian cancer , 1991, Cancer.

[84]  M. King,et al.  Linkage of early-onset familial breast cancer to chromosome 17q21. , 1990, Science.

[85]  M. Piver,et al.  Cisplatin-based chemotherapy for stage II ovarian adenocarcinoma: a preliminary report. , 1990 .

[86]  L. Strong,et al.  Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. , 1990, Science.

[87]  J. Minna,et al.  Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group. , 1990, Oncogene.

[88]  K. Hatch,et al.  c-myc amplification in ovarian cancer. , 1990, Gynecologic oncology.

[89]  B. Vogelstein,et al.  Suppression of human colorectal carcinoma cell growth by wild-type p53. , 1990, Science.

[90]  R. Bast,et al.  Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. , 1990, Cancer research.

[91]  I. Strøyer,et al.  Randomized study of whole-abdomen irradiation versus pelvic irradiation plus cyclophosphamide in treatment of early ovarian cancer. , 1990, Gynecologic oncology.

[92]  M. Schemper,et al.  Prognostic factors for survival in Stage I epithelial ovarian carcinoma , 1990 .

[93]  R. Knapp,et al.  Sonographic accuracy in the diagnosis of ovarian masses. , 1990, The Journal of reproductive medicine.

[94]  J. H. Lee,et al.  Frequent loss of heterozygosity on chromosomes 6q, 11, and 17 in human ovarian carcinomas. , 1990, Cancer research.

[95]  S. Ellenberg,et al.  Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials , 1990, The New England journal of medicine.

[96]  A. Stenwig,et al.  Prognostic Factors in Patients With Stage I Epithelial Ovarian Cancer , 1990, Obstetrics and gynecology.

[97]  F. Collins,et al.  Mutations in the p53 gene occur in diverse human tumour types , 1989, Nature.

[98]  T. Bourne,et al.  Transvaginal colour flow imaging: a possible new screening technique for ovarian cancer. , 1989, BMJ.

[99]  M. Piver,et al.  Adjuvant cisplatin-based chemotherapy for stage I ovarian adenocarcinoma: a preliminary report. , 1989, Gynecologic oncology.

[100]  V. Beral,et al.  Risk factors for ovarian cancer: a case-control study. , 1989, British Journal of Cancer.

[101]  G. Sutton,et al.  Surgical staging of carcinoma of the ovaries. , 1989, Surgery, gynecology & obstetrics.

[102]  P. Hartge,et al.  A case-control study of epithelial ovarian cancer. , 1989, American journal of obstetrics and gynecology.

[103]  T. Hata,et al.  Doppler ultrasound assessment of tumor vascularity in gynecologic disorders. , 1989, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.

[104]  J. Wils,et al.  Chemotherapy Consisting of Cisplatin, Doxorubicin, and Cyclophosphamide as an Adjunct to Surgery in Stage Ic‐II Epithelial Ovarian Carcinoma , 1989, American journal of clinical oncology.

[105]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[106]  L. Enk,et al.  Ultrasound‐guided puncture of cystic tumors in the lower pelvis of young women , 1989, Journal of clinical ultrasound : JCU.

[107]  A. Kurjak,et al.  Transvaginal Color Doppler For The Assessment Of Pelvic Circulation , 1989, Acta obstetricia et gynecologica Scandinavica.

[108]  R. Bast,et al.  Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses: discrimination of benign from malignant disease. , 1988, American journal of obstetrics and gynecology.

[109]  M. E. Kirk,et al.  Early stage ovarian cancer: a randomized clinical trial comparing whole abdominal radiotherapy, melphalan, and intraperitoneal chromic phosphate: a National Cancer Institute of Canada Clinical Trials Group report. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[110]  R. Park,et al.  Determinants of survival of patients with epithelial ovarian carcinoma following whole abdomen irradiation (WAR). , 1988, Gynecologic oncology.

[111]  R. Peschel,et al.  Postoperative abdominopelvic radiation therapy for ovarian cancer. , 1988, International journal of radiation oncology, biology, physics.

[112]  O. Kallioniemi,et al.  Prognostic significance of dna index, multiploidy, and S‐phase fraction in ovarian cancer , 1988, Cancer.

[113]  W. Sause,et al.  Analysis of postoperative radiation therapy in stage I through III epithelial ovarian carcinoma. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[114]  L. Banks,et al.  Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression. , 1986, European journal of biochemistry.

[115]  H. Norris,et al.  Misstaging of Ovarian Cancer , 1985, Obstetrics and gynecology.

[116]  A. Stenwig,et al.  EARLY STAGE OVARIAN CANCER , 1985, Acta obstetricia et gynecologica Scandinavica.

[117]  A. Dembo.  Radiotherapeutic management of ovarian cancer. , 1984, Seminars in oncology.

[118]  P. Nasca,et al.  An epidemiologic case-control study of ovarian cancer and reproductive factors. , 1984, American journal of epidemiology.

[119]  B. Edwards,et al.  Staging laparotomy in early ovarian cancer. , 1983, JAMA.

[120]  D. Rochester,et al.  Sonography of ovarian tumors: predictability of tumor type. , 1983, AJR. American journal of roentgenology.

[121]  R. Bast,et al.  A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. , 1983, The New England journal of medicine.

[122]  S. Shapiro,et al.  Epithelial ovarian cancer and combination oral contraceptives. , 1982, JAMA.

[123]  J. Liff,et al.  Incidence of ovarian cancer in relation to the use of oral contraceptives , 1981, International journal of cancer.

[124]  F. Mettler,et al.  Preoperative sonography of malignant ovarian neoplasms. , 1981, AJR. American journal of roentgenology.

[125]  H. Meire,et al.  DISTINCTION OF BENIGN FROM MALIGNANT OVARIAN CYSTS BY ULTRASOUND , 1978, British journal of obstetrics and gynaecology.

[126]  K. Stevens,et al.  Limited epithelial carcinoma of the ovary treated with curative intent by the intraperitoneal installation of radiocolloids , 1978, Cancer.

[127]  L. Delclos,et al.  Postoperative treatment of early cancer of the ovary: a random trial between postoperative irradiation and chemotherapy. , 1975, National Cancer Institute monograph.

[128]  D. Decker,et al.  Factors influencing survival in Stage I ovarian cancer , 1973 .

[129]  M F Fathalla,et al.  Incessant ovulation--a factor in ovarian neoplasia? , 1971, Lancet.

[130]  A. Knudson.  Mutation and cancer: statistical study of retinoblastoma. , 1971, Proceedings of the National Academy of Sciences of the United States of America.

[131]  P. Buell,et al.  Cancer mortality among Japanese ISSEI and NISEI of California , 1965, Cancer.

[132]  W. C. Keettel,et al.  DIAGNOSTIC VALUE OF PERITONEAL WASHINGS , 1958, Clinical obstetrics and gynecology.

[133]  D. Easton,et al.  Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. , 1995, American journal of human genetics.

[134]  F. Collins,et al.  Somatic mutations in the BRCA1 gene in sporadic ovarian tumours , 1995, Nature Genetics.

[135]  A. Whittemore,et al.  An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Breast Cancer Linkage Consortium. , 1995, American journal of human genetics.

[136]  I. Timor-Tritsch,et al.  Transvaginal ultrasonographic characterization of ovarian masses with an improved, weighted scoring system. , 1994, American journal of obstetrics and gynecology.

[137]  Y. Nakamura,et al.  Detailed deletion mapping of chromosome 17q in ovarian and breast cancers: 2-cM region on 17q21.3 often and commonly deleted in tumors. , 1993, Cancer research.

[138]  J. Skołyszewski,et al.  External beam radiotherapy in the management of ovarian carcinoma. , 1993, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[139]  P. Humphrey,et al.  Mutation and overexpression of p53 in early-stage epithelial ovarian cancer. , 1993, Obstetrics and gynecology.

[140]  T. Tong,et al.  Cancer statistics, 1993 , 1993, CA: a cancer journal for clinicians.

[141]  A. Zeleniuch‐Jacquotte,et al.  Contralateral ovary in unilateral ovarian carcinoma: a search for preneoplastic lesions. , 1993 .

[142]  M. Wikland,et al.  Comparison of endovaginal ultrasound and cytological evaluation of cystic ovarian tumors. , 1991, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.

[143]  Medicine,et al.  Overexpression and mutation of p53 in epithelial ovarian cancer. , 1991, Cancer research.

[144]  A. Gadducci,et al.  Adjuvant treatment of early stage ovarian carcinoma. , 1990, Clinical and experimental obstetrics & gynecology.

[145]  U. Nieminen,et al.  Does rupture of cystic carcinoma during operation influence the prognosis? , 1968, Annales chirurgiae et gynaecologiae Fenniae.